Dana Reddy, MD
Rheumatology · San Diego, CANPI 1144538778
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,155 and has fallen 51.6% since, to $559 in 2025.
Across 103 payments — averaging $34.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$694
- AbbVie$694
- Novartis$402
- Lilly USA, LLC$348
- GSK$320
- Johnson & Johnson$275
- plus $790 from 8 others
Across 16 payments — averaging $10,504 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Swing Therapeutics, Inc.$168K
What the payments were for
- Food & beverage$3,522100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 26 | $694 |
| AbbVie | 14 | $694 |
| Novartis | 13 | $402 |
| Lilly USA, LLC | 13 | $348 |
| GSK | 7 | $320 |
| Johnson & Johnson | 9 | $275 |
| Pfizer | 7 | $242 |
| UCB, Inc. | 6 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $100 |
| Sanofi | 2 | $86 |
| AstraZeneca | 2 | $44 |
| Boehringer Ingelheim | 1 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,522 in reported general payments places this provider in the 55th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 51 | $1,946 |
| MethotrexateMethotrexate Sodium | 19 | $430 |
| Prednisone | 29 | $232 |
| Colchicine | 11 | $159 |
| Alendronate Sodium | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in San Diego
- Ara DikranianSan Diego$2.2M
- Arthur MabaquiaoSan Diego$209K
- Kenneth KalunianSan Diego$194K
- Sudhakar TumuluriSan Francisco$2.8M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.